BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Carnitine palmitoyl transferase 1 (CPT1)

May 5, 2016 7:00 AM UTC

Cell culture and mouse studies suggest inhibiting CPT1 could help treat cachexia in cancer patients. In a xenograft mouse model of kidney cancer-associated cachexia and a mouse model of lung cancer-associated cachexia, a CPT1 inhibitor tool compound decreased weight loss and markers of disease progression in muscle and increased muscle mass compared with vehicle. Next steps could include testing CPT1 inhibitors in additional models of cancer-associated cachexia.

Heart Metabolics Ltd. has perhexiline, an inhibitor of CPT1 and CPT2, in Phase II testing to treat cardiomyopathy...